Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATH-399A
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Hanall Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...
Brand Name : ATH-399A
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 25, 2023
Lead Product(s) : ATH-399A
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Hanall Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?